Fracheboud J, de Koning H J, Beemsterboer P M, Boer R, Hendriks J H, Verbeek A L, van Ineveld B M, de Bruyn A E, van der Maas P J
Department of Public Health, Erasmus University, Rotterdam, The Netherlands.
Int J Cancer. 1998 Mar 2;75(5):694-8. doi: 10.1002/(sici)1097-0215(19980302)75:5<694::aid-ijc6>3.0.co;2-u.
Based on an extensive cost-effectiveness analysis, the Dutch nation-wide breast cancer screening programme started in 1990, providing a biennial screen examination to women aged 50 to 69 years. The programme is monitored by the National Evaluation Team, which annually collects tabulated regional evaluation data to determine performance indicators. This study presents (trends in) the outcomes of initial and subsequent screening rounds, 1990-1995, and compares them to the predictions of the cost-effectiveness-analysis. Up to 1996, 88% of the target population was covered by the programme and more than 2.4 x 10(6) women were invited. The overall attendance rate was 77.5% with little differences between screening rounds and age groups; the highest rate was found in non-urbanised areas (82.4%). Of 1,000 initially (and 2 years thereafter) screened women, 13.4 (6.6) were referred for further investigation, 9.7 (4.4) were biopsied and 6.4 (3.4) had breast cancer. The positive predictive values of screen test and biopsy were 47% (51%) and 66% (78%), respectively. DCIS was diagnosed in 0.9 (0.5) and invasive cancers < or = 10 mm in 1.5 (1.0) per 1,000 screens. Lymph node metastases were found in 28% (24%) of the invasive cancers. Except the increasing attendance, which was much higher than expected, the results were fairly constant over the years. Contrary to initial screens, the results of subsequent screens did not fulfil expectations with regard to breast cancer detection and tumour size distribution. We conclude that the nation-wide screening programme is being implemented successfully. Given the results, the programme should contribute to a substantial breast cancer mortality reduction in the future. The discrepancy between observed and expected results in subsequent screens has to be watched carefully.
基于广泛的成本效益分析,荷兰全国性乳腺癌筛查项目于1990年启动,为50至69岁的女性提供两年一次的筛查检查。该项目由国家评估团队进行监测,该团队每年收集列表形式的区域评估数据以确定绩效指标。本研究展示了1990 - 1995年首轮及后续筛查轮次的结果(趋势),并将其与成本效益分析的预测结果进行比较。截至1996年,该项目覆盖了88%的目标人群,超过240万女性被邀请参加筛查。总体参与率为77.5%,各筛查轮次和年龄组之间差异不大;非城市化地区的参与率最高(82.4%)。在最初(及此后两年)接受筛查的1000名女性中,有13.4(6.6)人被转诊进行进一步检查,9.7(4.4)人接受了活检,6.4(3.4)人患有乳腺癌。筛查试验和活检的阳性预测值分别为47%(51%)和66%(78%)。每1000次筛查中,导管原位癌(DCIS)的诊断率为0.9(0.5),浸润性癌≤10mm的诊断率为1.5(1.0)。28%(24%)的浸润性癌发现有淋巴结转移。除了参与率不断上升且远高于预期外,这些年的结果相当稳定。与首轮筛查相反,后续筛查在乳腺癌检测和肿瘤大小分布方面的结果未达预期。我们得出结论,全国性筛查项目正在成功实施。鉴于这些结果,该项目未来应有助于大幅降低乳腺癌死亡率。后续筛查中观察到的结果与预期结果之间的差异必须密切关注。